TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
BetterLife Pharma ( (TSE:BETR) ) just unveiled an update.
BetterLife Pharma Inc. has announced the issuance of 57,945 common shares and share purchase warrants as part of a debt conversion related to accrued interest on convertible debentures. The company also reported the resignation of Mr. André Beaudry from its Board of Directors and plans to appoint new corporate advisors soon. These developments are part of BetterLife’s ongoing efforts to strengthen its financial position and governance as it continues to focus on its core projects in neurological disorder treatments.
Spark’s Take on TSE:BETR Stock
According to Spark, TipRanks’ AI Analyst, TSE:BETR is a Underperform.
BetterLife Pharma is currently in a precarious financial position with no revenue, substantial losses, and a high leverage risk due to negative equity. Technical indicators show a lack of momentum, and the valuation is unattractive due to negative earnings. The overall outlook is negative, reflecting significant financial instability.
To see Spark’s full report on TSE:BETR stock, click here.
More about BetterLife Pharma
BetterLife Pharma Inc. is an emerging biotechnology company focused on developing and commercializing BETR-001, a non-hallucinogenic LSD derivative for treating neurological disorders. The company holds a synthesis patent for BETR-001, which is unregulated and can be self-administered, and is seeking strategic alternatives for a drug candidate targeting viral infections.
Average Trading Volume: 108,944
Technical Sentiment Signal: Sell
Current Market Cap: C$10.63M
For a thorough assessment of BETR stock, go to TipRanks’ Stock Analysis page.